Volastra Therapeutics shared a post on LinkedIn:

“We are proud to announce that we dosed the first ovarian cancer patient in a Phase 1b clinical trial for our KIF18A inhibitor, sovilnesib, and celebrate this major milestone in our fight against cancer. ”

⁠Proceed to the video attached to the post.
Source: Volastra Therapeutics/LinkedIn

About OncoDaily

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”